Related Experiment Video
Updated: Sep 3, 2025
09:04
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
649
Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors
Sriram Gubbi1, Namrata Vijayvergia2, Jian Q Yu3
1Endocrinology, National Institutes of Health Clinical Center, Bethesda, United States.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|July 25, 2022
Summary
Immune checkpoint inhibitor (ICI) therapy is a new option for neuroendocrine tumors (NETs). Research is ongoing to determine if ICI therapy is more effective or safer than current NET treatments.
Area of Science:
- Oncology
- Immunotherapy
- Molecular Biology
Background:
- Neuroendocrine tumors (NETs) exhibit diverse clinical and biochemical features, with incompletely understood molecular drivers.
- Current NET management includes surgery, locoregional interventions, and various systemic therapies like chemotherapy and targeted agents.
Approach:
- This review synthesizes current evidence regarding the efficacy and safety of immune checkpoint inhibitor (ICI) therapy in NET management.
- It highlights the challenges in identifying NETs that may benefit from ICI treatment.
Key Points:
- The role of ICI therapy in NETs is an emerging area of research.
- Comparative data on ICI efficacy and safety versus established systemic therapies for NETs are limited.
- Predictive biomarkers for ICI response in NETs remain to be identified.
Conclusions:
- Further research is needed to clarify the distinct advantages, if any, of ICI therapy for NETs.
- Identifying specific NET characteristics predictive of ICI response is crucial for clinical application.
- This review aims to guide future investigations into optimizing ICI therapy for neuroendocrine tumors.
Related Concept Videos
01:27Tumor Immunotherapy
652
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
256
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
256
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K